Cargando…
Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tunisian Society of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003587/ https://www.ncbi.nlm.nih.gov/pubmed/35261014 |
_version_ | 1784686163250905088 |
---|---|
author | Gaies, Emna Zgolli, Fatma Charfi, Rim Ben Sassi, Mouna EL Jebari, Hanene Salouage, Issam Daghfous, Riadh Trabelsi, Sameh |
author_facet | Gaies, Emna Zgolli, Fatma Charfi, Rim Ben Sassi, Mouna EL Jebari, Hanene Salouage, Issam Daghfous, Riadh Trabelsi, Sameh |
author_sort | Gaies, Emna |
collection | PubMed |
description | Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in epileptic adults. Methods: We performed a retrospective study over a period of 9 years in the Department of Clinical Pharmacology in the Tunisian National Centre “Chalbi Belkahia” of Pharmacovigilance. Our study included samples from adult patients receiving CBZ alone or associated to other AED for epilepsy. Trough plasma CBZ plasma concentrations were measured by an immunological method. Included samples were divided in four groups: i/ group 1 (G1) receiving CBZ as monotherapy, ii/ group 2 (G2) treated by CBZ with an enzyme inducer (phenobarbital or phenytoin), iii/ group 3 (G3) taking CBZ associated to an enzyme inhibitor (valproic acid (VPA)), iv/ group 4 (G4), treated by CBZ associated to enzyme inducer (phenobarbital or phenytoin) and enzyme inhibitor (valproic acid) at the same time. Results: There were no significant differences between different groups in age, weight and sex ratio. However statistical analysis showed a significant decrease in C0/D CBZ ratio between G1 and G2 and between G1 and G4 (p<0.001). However, the difference was not significant between G1 and G3 (p=1.2044). Conclusion: It is important to check and to prevent the consequences of the interaction between CBZ and other AED in order to avoid inefficiency and toxicity. |
format | Online Article Text |
id | pubmed-9003587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Tunisian Society of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-90035872022-04-15 Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients Gaies, Emna Zgolli, Fatma Charfi, Rim Ben Sassi, Mouna EL Jebari, Hanene Salouage, Issam Daghfous, Riadh Trabelsi, Sameh Tunis Med Article Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in epileptic adults. Methods: We performed a retrospective study over a period of 9 years in the Department of Clinical Pharmacology in the Tunisian National Centre “Chalbi Belkahia” of Pharmacovigilance. Our study included samples from adult patients receiving CBZ alone or associated to other AED for epilepsy. Trough plasma CBZ plasma concentrations were measured by an immunological method. Included samples were divided in four groups: i/ group 1 (G1) receiving CBZ as monotherapy, ii/ group 2 (G2) treated by CBZ with an enzyme inducer (phenobarbital or phenytoin), iii/ group 3 (G3) taking CBZ associated to an enzyme inhibitor (valproic acid (VPA)), iv/ group 4 (G4), treated by CBZ associated to enzyme inducer (phenobarbital or phenytoin) and enzyme inhibitor (valproic acid) at the same time. Results: There were no significant differences between different groups in age, weight and sex ratio. However statistical analysis showed a significant decrease in C0/D CBZ ratio between G1 and G2 and between G1 and G4 (p<0.001). However, the difference was not significant between G1 and G3 (p=1.2044). Conclusion: It is important to check and to prevent the consequences of the interaction between CBZ and other AED in order to avoid inefficiency and toxicity. Tunisian Society of Medical Sciences 2021-08 2021-08-01 /pmc/articles/PMC9003587/ /pubmed/35261014 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Article Gaies, Emna Zgolli, Fatma Charfi, Rim Ben Sassi, Mouna EL Jebari, Hanene Salouage, Issam Daghfous, Riadh Trabelsi, Sameh Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients |
title | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients |
title_full | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients |
title_fullStr | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients |
title_full_unstemmed | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients |
title_short | Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients |
title_sort | drug interaction between carbamazepine and other antiepileptic drugs in tunisian epileptic patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003587/ https://www.ncbi.nlm.nih.gov/pubmed/35261014 |
work_keys_str_mv | AT gaiesemna druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT zgollifatma druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT charfirim druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT bensassimouna druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT eljebarihanene druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT salouageissam druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT daghfousriadh druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients AT trabelsisameh druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients |